Skip to main content

Table 2 Preclinical testing of PARP inhibitors and other inhibitors of base excision repair

From: Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms

Agent

Mechanism

Cancer cell lines/tumor models

Agents potentiated

References

ABT-888

PARP inhibition

Breast, lung, ovarian, colon, melanoma, glioma

TMZ, cisplatin, carboplatin, irinotecan, cyclophosphamide, IR

[57, 62, 63]

AG14361

PARP inhibition

Lung, colorectal

TMZ, topotecan, irinotecan, IR

[56]

CEP-6800

PARP inhibition

Colon, GBM, NSCLC

TMZ, irinotecan, cisplatin

[58]

CEP-8983

PARP inhibition

GBM, colon, rhabdomyosarcoma, neuroblastoma

TMZ, camptothecin, irinotecan

[85]

INO-1001

PARP inhibition

Breast, GBM, sarcoma

TMZ, doxorubicin, IR

[55, 64]

Lithocholic acid

DNA pol-β inhibition

BRCA2-deficient Chinese hamster ovary cells

TMZ

[59]

Methoxyamine

AP site binding

Colon

TMZ, BCNU

[68]

  1. AP, apurininc/pyrimidinic; BCNU, 1,3-bis(chloroethyl)-1-nitrosourea; GBM, glioblastoma multiforme; IR, ionizing radiation; NSCLC, nucleotide excision repair; PARP, poly(ADP-ribose) polymerase; TMZ, temozolomide.